Ask anyone in the weed game, from the dime bag dealers to CEO’s of big publicly traded companies and they’ll tell you: it’s always rough starting out. So, it’s no surprise that the same is true for the Drug Enforcement Administration (DEA).

A national cannabis trade organization is opposing the DEA’s proposed entry into the cannabis industry.

In March, the DEA announced a plan to essentially become a weed business itself, serving as a middleman which bought and sold all cannabis used in U.S. medical research. The DEA would own all medical weed used in the United States.

The proposal allowed for a comment period until late May. Now, the National Cannabis Industry Association (NCIA) has made its comment, and that comment is “Nah, brah.”

“One of the many qualified public health agencies in the federal government (i.e. Health and Human Services, National Institutes of Health, etc.) should manage all of the processes related to research into the medicinal benefits of cannabis, including making decisions about who might qualify to grow and sell the product to researchers,” the NCIA said in a statementto the DEA.

“This is perfectly consistent with US [global drug control] treaty obligations. Furthermore, the US should adopt a regulatory framework that encourages and facilitates further research, rather than chilling it.”

They don’t think an agency which has spent decades hunting down cannabis businesses, including state-legalized ones, should be in charge of the supply chain for medical weed. That might not be the people who would be most willing and able to nurture the immensely promising field of cannabis research. Instead, maybe leave that to the health experts.

Photo via Flickr/WeedPornDaily